

## OMONTYS PRESERVATIVE FREE - (1MG/0.5ML, 2MG/0.5ML, 3MG/0.5ML, 4MG/0.5ML, 5MG/0.5ML, 6MG/0.5ML ; Solution)

<b>Generic Name</b>	PEGINESATIDE ACETATE	<b>Innovator</b>	Takeda
<b>Dosage</b>	1MG/0.5ML, 2MG/0.5ML, 3MG/0.5ML, 4MG/0.5ML, 5MG/0.5ML, 6MG/0.5ML ; Solution	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	OMONTYS is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.